acute pancreatitis / upper abdominal pain, nausea and vomiting;   A 46 year-old male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. Relevant medical history included: "upper abdominal pain" (unspecified if ongoing); "nausea" (unspecified if ongoing); "vomiting" (unspecified if ongoing); "hospitalization" (unspecified if ongoing); "drinks 2 beers weekly" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: PANCREATITIS ACUTE (hospitalization, medically significant), outcome "recovering", described as "acute pancreatitis / upper abdominal pain, nausea and vomiting / peripancreatic inflammatory changes consistent with pancreatitis with a 5 cm complex thick-walled pseudocyst or walled off necrosis given the internal debris". The patient underwent the following laboratory tests and procedures: blood triglycerides: normal, notes: Normal; computerised tomogram: uncomplicated acute pancreatitis involving the dis, notes: uncomplicated acute pancreatitis involving the distal body and tail of the pancreas with normal biliary anatomy; computerised tomogram abdomen: showed peripancreatic inflammatory changes consist, notes: showed peripancreatic inflammatory changes consistent with pancreatitis with a 5 cm complex thick-walled pseudocyst or walled off necrosis given the internal debris; laboratory test: normal, notes: normal; lipase: 648 IU/l, notes: with normal LFTs; 45 IU/l, notes: on the day of discharge; 1483 IU/l; 233 IU/l, notes: on the day of discharge; liver function test: normal. Therapeutic measures were taken as a result of pancreatitis acute. Addition information: Patient was kept NPO and treated with analgesics and IV fluids. Lisinopril and HCTZ were discontinued. Patient was discharged with amlodipine. CT abdomen showed peripancreatic inflammatory changes consistent with pancreatitis with a 5 cm complex thick-walled pseudocyst or walled off necrosis given the internal debris. He was discharged after improvement with NPO, IV fluids and analgesics. He did well until after the second dose of vaccine. The patient received the second dose of BNT162B2 via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunization. His pain continued to worsen in a similar fashion as happened after the first dose of vaccine leading to hospitalization. It was reported that our goal was to make medical community aware of pancreatitis being one of the possible emerging side effects to the vaccine.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Based on temporal relationship the possibility of causal association between the reported events acute pancreatitis and the suspect drug BNT162B2 cannot be excluded.   The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : PFIZER INC-202101767144 Same Patient/article/drug/event